Who is accountable when a segmented medical device still exposes patient care risk?

Why This Matters for Security Teams

When a segmented medical device still exposes patient care risk, the issue is no longer just whether the network was separated correctly. It becomes a shared governance problem across security, biomedical engineering, clinical operations, and patient safety. Segmentation may reduce exposure, but it does not by itself prove the device is safe in its real operating context, especially when update paths, vendor support channels, or emergency workflows remain open.

This matters because healthcare environments often treat segmentation as a finished control instead of a risk-reduction measure that still needs validation. NIST Cybersecurity Framework 2.0 makes clear that governance and risk ownership must be explicit, not implied, and that control effectiveness should be tied to business outcomes, not only technical configuration. In practice, that means a device can be “compliant” from a network perspective while still creating unacceptable care risk if alarms, latency, maintenance access, or failover behavior have not been tested.

Security teams also need to distinguish between device connectivity risk and clinical harm. A segmented device can still be dangerous if it depends on fragile exceptions, shared management accounts, or vendor access that bypasses normal controls. That is why accountability should not be assigned only after an incident review. It should be established before deployment, before exceptions are granted, and before a device is accepted into production. In practice, many security teams encounter the accountability gap only after a device has already affected care, rather than through intentional control validation.

How It Works in Practice

Operational accountability works best when segmentation is treated as one layer in a broader safety and assurance process. Security usually owns the policy, architecture, monitoring, and logging for network zones. Clinical engineering or biomedical teams typically own device functionality, maintenance windows, and validation that the device still performs safely after isolation. Clinical leadership should define the acceptable care impact if the device loses a network dependency or cannot be patched immediately.

Good governance usually starts with a simple question: what risk is segmentation meant to reduce, and what new risk does it create? For example, isolating a device may reduce lateral movement, but it can also delay vendor diagnostics or emergency support. That tradeoff should be documented, approved, and periodically revalidated. NIST SP 800-53 Rev. 5 is useful here because it separates access control, system integrity, auditing, and contingency planning into distinct control families, which helps teams avoid assuming that one control satisfies every objective.

• Define one owner for the segmentation rule set and one owner for the clinical safety outcome.
• Record exceptions with expiry dates, compensating controls, and sign-off from the right clinical authority.
• Test device behavior after segmentation, not only before go-live.
• Monitor for vendor remote access, shared credentials, and unexpected management channels.
• Reassess the device after software updates, topology changes, and new clinical workflows.

Detection and response also matter. If a segmented device begins to fail or behave unexpectedly, the team needs a clear escalation path, not an argument over who changed the firewall rule. The most effective programs map these devices into NIST CSF 2.0 governance, identification, protection, detection, response, and recovery functions, so accountability is visible across the full lifecycle. That becomes even more important as AI-assisted diagnostics and autonomous workflow tools increase the number of systems that can influence patient care. These controls tend to break down when legacy devices depend on vendor tunnels and undocumented maintenance paths because segmentation is then only partial in practice.

Common Variations and Edge Cases

Tighter segmentation often increases operational overhead, requiring organisations to balance patient safety gains against uptime, access, and supportability. That tradeoff is especially visible in hospitals with legacy imaging, infusion, or monitoring devices that cannot be patched quickly or that require vendor connectivity for service.

There is no universal standard for this yet on exactly how much residual care risk is acceptable after segmentation, so current guidance suggests using a risk acceptance process that is specific, time-bound, and clinically informed. The most common edge case is a device that is technically segmented but still depends on a shared jump host, a remote support portal, or an outdated management protocol. In those environments, accountability becomes blurred unless someone explicitly owns the exception and validates the compensating controls.

Another edge case is shared responsibility with outsourced clinical engineering or managed security services. Contracting does not remove accountability. It only redistributes execution. The hospital still needs named decision-makers for change approval, clinical validation, incident escalation, and exception approval. NIST CSF 2.0 and NIST control guidance are useful anchors, but healthcare teams should also align this with safety governance and vendor assurance processes. For emerging AI-enabled medical workflows, the accountability question expands further because model outputs and automated actions can affect care even when the underlying device remains segmented. In those cases, governance should include both device assurance and AI output validation.

Related resources from NHI Mgmt Group

• Who is accountable when a shared clinical device exposes patient data?
• Who is accountable when poor IAM exposes patient data or disrupts care?
• Who is accountable when a medical device cyber issue affects patient safety?
• Who is accountable when a retired device still contains company data?